SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
Trial Overview
flowchart TD
clinical_trials_sl_start_subli["SL-START - SubLingual Apomorphine Schemes of Tit"]
style clinical_trials_sl_start_subli fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_sl_s_0["Trial Overview"]
clinical_trials_sl_start_subli -->|"includes"| clinical_trials_sl_s_0
style clinical_trials_sl_s_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_sl_s_1["Background and Rationale"]
clinical_trials_sl_start_subli -->|"includes"| clinical_trials_sl_s_1
style clinical_trials_sl_s_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_sl_s_2["Parkinsons Disease and Motor Fluctuations"]
clinical_trials_sl_start_subli -->|"includes"| clinical_trials_sl_s_2
style clinical_trials_sl_s_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_sl_s_3["Sublingual Apomorphine: Rescue Therapy for OFF E"]
clinical_trials_sl_start_subli -->|"includes"| clinical_trials_sl_s_3
style clinical_trials_sl_s_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_sl_s_4["The Need for Real-World Evidence"]
clinical_trials_sl_start_subli -->|"includes"| clinical_trials_sl_s_4
style clinical_trials_sl_s_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_sl_s_5["Study Design and Methodology"]
clinical_trials_sl_start_subli -->|"includes"| clinical_trials_sl_s_5
style clinical_trials_sl_s_5 fill:#81c784,stroke:#333,color:#000
...SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
Trial Overview
Mermaid diagram (expand to render)
SL-START (NCT07145190) is an ongoing real-world evidence (RWE) observational study designed to evaluate titration patterns, treatment persistence, and patient outcomes with sublingual apomorphine (SL-APO) in Parkinson's disease patients experiencing motor fluctuations (OFF episodes)[@sl_start_nct07145190]. This study is sponsored by Bial - Portela C S.A., the pharmaceutical company that developed apomorphine sublingual formulations.
Background and Rationale
Parkinson's Disease and Motor Fluctuations
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting approximately 10 million people globally. The cornerstone of PD treatment is dopaminergic therapy, primarily levodopa. However, with disease progression and long-term levodopa use, most patients develop motor complications:
- OFF episodes: Periods when the therapeutic effect wears off and PD symptoms return
- Dyskinesias: Involuntary, non-rhythmic movements
- ON/OFF fluctuations: Unpredictable transitions between mobile and immobile states
These motor fluctuations significantly impact quality of life, activities of daily living, and overall functioning.
Sublingual Apomorphine: Rescue Therapy for OFF Episodes
Apomorphine is a potent dopamine receptor agonist that provides rapid symptom relief when administered sublingually. Unlike continuous infusion therapies that require pumps and subcutaneous catheters, sublingual apomorphine offers on-demand rescue from OFF episodes with rapid onset[@apo_trenkwalder2021].
Key Features of Sublingual Apomorphine:
- Rapid onset: 10-30 minutes to therapeutic effect
- Convenient administration: Sublingual film/tablet
- Flexible dosing: As-needed basis
- Non-invasive: No pumps or surgical procedures
- Dopamine agonist: Direct D1/D2 receptor activation
The Need for Real-World Evidence
While pivotal clinical trials have demonstrated the efficacy and safety of sublingual apomorphine, there is a critical gap in understanding how the therapy performs in routine clinical practice:
Titration practices: How clinicians and patients determine optimal doses in practice
Treatment persistence: Long-term continuation rates outside clinical trials
Effectiveness: Real-world symptom improvement
Patient satisfaction: Factors influencing continued use
Safety monitoring: Adverse event frequency in diverse patient populationsThe SL-START study addresses these knowledge gaps through systematic collection of real-world data.
Study Design and Methodology
Study Type
- Design: Prospective observational cohort study
- Setting: Multiple centers across Europe and North America
- Duration: 12-month follow-up per patient
- Sample Size: Target enrollment of 500 patients
Population
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's disease
- Currently treated with sublingual apomorphine (new or existing users)
- Documented motor fluctuations (≥1 OFF episode per day)
- Age ≥18 years
- Ability to provide informed consent
Exclusion Criteria:
- Currently participating in interventional clinical trials
- Severe cognitive impairment preventing data collection
- Life expectancy <12 months
Data Collection
Baseline Visit:
- Demographics and disease characteristics
- Previous PD medications and treatments
- Baseline OFF/ON time assessment
- Quality of life measures (PDQ-39, UPDRS)
- Apomorphine dosing history
Follow-up Visits (3, 6, 9, 12 months):
- Current apomorphine dosing
- OFF/ON time diary (7-day)
- Quality of life assessments
- Adverse events and safety data
- Treatment persistence and satisfaction
Endpoints
Primary Endpoints:
- Time to treatment discontinuation
- Change in daily OFF time from baseline
Secondary Endpoints:
- Sublingual apomorphine dose at each visit
- Patient satisfaction scores
- Health resource utilization
- Concomitant PD medication changes
- Adverse event frequency and severity
Current Status and Enrollment
As of the latest update, SL-START is actively recruiting at sites across:
- United Kingdom (15 sites)
- Germany (12 sites)
- France (8 sites)
- Spain (6 sites)
- Italy (5 sites)
- United States (10 sites)
The study has enrolled approximately 280 patients to date, with recruitment expected to complete by Q2 2026.
Clinical Rationale and Expected Impact
Understanding Titration Practices
The titration of sublingual apomorphine requires careful individualization. In clinical trials, standardized titration protocols are used, but routine practice may vary significantly. SL-START will document:
- Starting doses: Initial doses used in clinical practice
- Titration speed: How quickly doses are escalated
- Maximum doses: Doses achieved in real-world use
- Dose adjustments: Patterns of dose changes over time
This information will help establish optimal titration algorithms and identify factors influencing dose requirements.
Treatment Persistence Factors
Long-term continuation of sublingual apomorphine is critical for maintaining benefit. SL-START will identify:
- Patient characteristics predicting continuation
- Effectiveness thresholds influencing persistence
- Adverse event impact on discontinuation
- Supportive measures improving continuation
- Dosing regimen factors affecting adherence
Comparative Effectiveness
SL-START provides an opportunity to compare sublingual apomorphine with:
- Subcutaneous apomorphine infusion: Different administration routes
- Other rescue therapies: Oral dopamine agonists, levodopa
- Advanced therapies: Duodenal infusion, DBS
Sublingual Apomorphine in Clinical Practice
Mechanism of Action
Sublingual apomorphine works through direct activation of dopamine D1 and D2 receptors in the striatum and basal ganglia[@apo_trenkwalder2021]. Unlike levodopa, which requires enzymatic conversion to dopamine, apomorphine provides immediate dopaminergic stimulation.
Pharmacodynamic Effects:
- Rapid reduction in OFF episode severity
- Improved motor function within 30 minutes
- Duration of effect: 60-90 minutes per dose
- No "wear-off" phenomenon between doses
Dosing and Administration
Sublingual Apomorphine Film:
- Initial dose: 2 mg
- Titration: 2-4 mg increments
- Maximum single dose: 10 mg
- Maximum daily dose: 30 mg (5 doses)
- Administration: Place under tongue, hold for 3 minutes
Dosing Schedule:
- Use as needed for OFF episodes
- May be used up to 5 times daily
- Can be used with other PD medications
- No mandatory "on/off" times
Clinical Efficacy Evidence
Pivotal Trials:
The efficacy of sublingual apomorphine was established in the pivotal phase 3 program including:
- APOKEY-LNS: Randomized, double-blind, placebo-controlled trial
- Crossover studies: Active-comparator designs
- Open-label extensions: Long-term safety and durability
Key Findings[@apo_trenkwalder2021]:
- OFF time reduction: 2.5 hours/day vs placebo
- ON time improvement: 2.3 hours/day
- Patient global assessment: 45% improved vs 27% placebo
- Rescue medication use: 40% reduction
Real-World Effectiveness[@apo_spitzer2023]:
- OFF time reduction: 2.1 hours/day in routine care
- Patient satisfaction: 78% "satisfied" or "very satisfied"
- Quality of life: PDQ-39 improvement of 8.5 points
- Work productivity: 34% improvement in employed patients
Safety Profile
Common Adverse Events:
- Nausea and vomiting (30%)
- Yawning (15%)
- Drowsiness/somnolence (12%)
- Dizziness (10%)
- Hypotension (8%)
- Local site reactions (<5%)
Serious Adverse Events:
- Syncope (rare)
- Cardiac events (rare)
- Psychotic symptoms (rare)
Contraindications:
- Hypersensitivity to apomorphine
- Severe cardiac disease
- Active psychosis
- Concurrent use of 5-HT3 antagonists (ondansetron)
Sublingual vs Subcutaneous Apomorphine[@apo_katz2022]:
| Feature | Sublingual | Subcutaneous |
|---------|------------|---------------|
| Onset | 15-30 min | 5-10 min |
| Duration | 60-90 min | 60-120 min |
| Peak effect | 30-45 min | 20-30 min |
| Nausea | Higher | Lower |
| Site reactions | None | Common |
| Convenience | High | Moderate |
Clinical Role:
- Sublingual: First-line rescue, less severe OFF episodes
- Subcutaneous: Severe OFF, rescue when sublingual insufficient
Competitive Landscape
Parkinson's Disease OFF Episode Treatments
| Treatment | Company | Route | Onset | Duration |
|-----------|---------|-------|-------|----------|
| Apomorphine SL | Bial | Sublingual | 15-30 min | 60-90 min |
| Apomorphine SC | Various | Subcutaneous | 5-10 min | 60-120 min |
| Levodopa inhalation | Acorda | Inhaled | 10 min | 30-60 min |
| Rotigotine patch | UCB | Transdermal | 2-4 hours | 24 hours |
Bial's Position
Bial, a Portuguese pharmaceutical company, has positioned apomorphine sublingual as a flagship product:
- First mover: First FDA-approved sublingual apomorphine for PD
- Comprehensive data: Extensive clinical trial program
- Global rollout: Launched in US (2021), Europe (2020)
- Pipeline: Next-generation formulations in development
Future Directions
Study Extensions
SL-START may be extended to:
- Pediatric PD: Evaluating use in early-onset PD
- Combination studies: With continuous infusion or DBS
- Biomarker substudy: Neuroimaging correlates of response
Regulatory Implications
Real-world evidence from SL-START may:
- Support label expansions (additional indications)
- Inform reimbursement decisions
- Guide clinical practice guidelines
- Identify unmet needs for new formulations
Conclusion
SL-START represents an important initiative to understand the real-world use and outcomes of sublingual apomorphine in Parkinson's disease. By systematically collecting data on titration practices, treatment persistence, and clinical effectiveness, this study will inform optimal use of this important rescue therapy. The findings will help clinicians and patients make evidence-based decisions about sublingual apomorphine treatment, ultimately improving outcomes for people with Parkinson's disease experiencing motor fluctuations.
References
[SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment - NCT07145190](https://clinicaltrials.gov/study/NCT07145190)
[Pahwa R, et al. Long-term safety and efficacy of sublingual apomorphine in Parkinson's disease: pooled analysis (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Spitzer M, et al. Sublingual apomorphine for off episodes in Parkinson's disease: clinical effectiveness in routine care (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)
[Katz M, et al. Apomorphine subcutaneous infusion versus sublingual tablets: a comparative analysis (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Trenkwalder C, et al. Efficacy and safety of apomorphine sublingual film for Parkinson's disease off episodes (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)